Population pharmacokinetic study of gentamicin in a large cohort of premature and term neonates

British Journal of Clinical Pharmacology

Volumn 78, Issue 5, 2014, Pages 1090-1101

  Fuchs, Aline ^a   Guidi, Monia ^a,b   Giannoni, Eric ^a   Werner, Dominique ^a   Buclin, Thierry ^a   Widmer, Nicolas ^a   Csajka, Chantal ^a,b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Aminoglycoside; Dosing guidelines; Neonates; Population pharmacokinetics; Therapeutic drug monitoring; Two compartment model

Indexed keywords

AMIKACIN; DOPAMINE; FUROSEMIDE; GENTAMICIN; IBUPROFEN; INDOMETACIN; ANTIINFECTIVE AGENT;

ALLOMETRY; ARTICLE; BAYESIAN LEARNING; BODY WEIGHT; COHORT ANALYSIS; COMPARTMENT MODEL; COMPUTER SIMULATION; CONTROLLED STUDY; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG MONITORING; ENVIRONMENTAL FACTOR; GESTATIONAL AGE; HUMAN; INDIVIDUALIZATION; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; NEWBORN; PHYSIOLOGICAL PROCESS; POPULATION RESEARCH; PRACTICE GUIDELINE; PREMATURITY; RETROSPECTIVE STUDY; STEADY STATE; TERM BIRTH; VOLUME OF DISTRIBUTION; BIOLOGICAL MODEL; BIRTH WEIGHT; BLOOD; DOSE RESPONSE; FLUORESCENCE POLARIZATION IMMUNOASSAY; METABOLIC CLEARANCE RATE; PERSONALIZED MEDICINE; REGRESSION ANALYSIS;

ANTI-BACTERIAL AGENTS; BIRTH WEIGHT; BODY WEIGHT; COHORT STUDIES; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENTAMICINS; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PRECISION MEDICINE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES;

EID: 84919388481     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12444     Document Type: Article

References (72)

1. Lopez-Novoa JM, Quiros Y, Vicente L, Morales AI, Lopez-Hernandez FJ. New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view. Kidney Int 2011; 79: 33-45.
2. Schultze RG, Winters RE, Kauffman H. Possible nephrotoxicity of gentamicin. J Infect Dis 1971; 124 (Suppl.): S145-7.
3. Wilfert JN, Burke JP, Bloomer HA, Smith CB. Renal insufficiency associated with gentamicin therapy. J Infect Dis 1971; 124 (Suppl.): S148-55.
4. Banck G, Belfrage S, Juhlin I, Nordstrom L, Tjernstrom O, Toremalm NG. Retrospective study of the ototoxicity of gentamicin. Acta Pathol Microbiol Scand B Microbiol Immunol 1973; (Suppl. 241): 54-7.
5. Borradori C, Fawer CL, Buclin T, Calame A. Risk factors of sensorineural hearing loss in preterm infants. Biol Neonate 1997; 71: 1-10.
6. Polin RA, Committee on F, Newborn. Management of neonates with suspected or proven early-onset bacterial sepsis. Pediatrics 2012; 129: 1006-15.
7. Stocker M, Berger C, McDougall J, Giannoni E. Taskforce for the Swiss Society of N, the Paediatric Infectious Disease Group of S. Recommendations for term and late preterm infants at risk for perinatal bacterial infection. Swiss Med Wkly 2013; 143: w13873.
8. Pagkalis S, Mantadakis E, Mavros MN, Ammari C, Falagas ME. Pharmacological considerations for the proper clinical use of aminoglycosides. Drugs 2011; 71: 2277-94.
9. Bailey DN, Briggs JR. Gentamicin and tobramycin binding to human serum in vitro. J Anal Toxicol 2004; 28: 187-9.
10. Gordon RC, Regamey C, Kirby WM. Serum protein binding of the aminoglycoside antibiotics. Antimicrob Agents Chemother 1972; 2: 214-6.
11. Riff LJ, Jackson GG. Pharmacology of gentamicin in man. J Infect Dis 1971; 124 (Suppl.): S98-105.
12. Black MJ, Sutherland MR, Gubhaju L, Kent AL, Dahlstrom JE, Moore L. When birth comes early: effects on nephrogenesis. Nephrology (Carlton) 2013; 18: 180-2.
13. Guignard JP, Drukker A. Why do newborn infants have a high plasma creatinine Pediatrics 1999; 103: e49.
14. Kyser KL, Morriss FH, Jr., Bell EF, Klein JM, Dagle JM. Improving survival of extremely preterm infants born between 22 and 25 weeks of gestation. Obstet Gynecol 2012; 119: 795-800.
15. Cuzzolin L, Fanos V, Pinna B, di Marzio M, Perin M, Tramontozzi P, Tonetto P, Cataldi L. Postnatal renal function in preterm newborns: a role of diseases, drugs and therapeutic interventions. Pediatr Nephrol 2006; 21: 931-8.
16. Besunder JB, Reed MD, Blumer JL. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II). Clin Pharmacokinet 1988; 14: 261-86.
17. Friis-Hansen B. Body water compartments in children: changes during growth and related changes in body composition. Pediatrics 1961; 28: 169-81.
18. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157-67.
19. Sheiner LB, Beal S, Rosenberg B, Marathe VV. Forecasting individual pharmacokinetics. Clin Pharmacol Ther 1979; 26: 294-305.
20. Pons G, Treluyer JM, Dimet J, Merle Y. Potential benefit of Bayesian forecasting for therapeutic drug monitoring in neonates. Ther Drug Monit 2002; 24: 9-14.
21. Touw DJ, Westerman EM, Sprij AJ. Therapeutic drug monitoring of aminoglycosides in neonates. Clin Pharmacokinet 2009; 48: 71-88.
22. Fuchs A, Csajka C, Thoma Y, Buclin T, Widmer N. Benchmarking therapeutic drug monitoring software: a review of available computer tools. Clin Pharmacokinet 2013; 52: 9-22.
23. Sawchuk RJ, Zaske DE, Cipolle RJ, Wargin WA, Strate RG. Kinetic model for gentamicin dosing with the use of individual patient parameters. Clin Pharmacol Ther 1977; 21: 362-9.
24. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokinet 1996; 30: 329-32.
25. Lindbom L, Pihlgren P, PsN JEN. Toolkit-a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput Methods Programs Biomed 2005; 79: 241-57.
26. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011; 13: 143-51.
27. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51-64.
28. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981; 9: 503-12.
29. McLeay SC, Morrish GA, Kirkpatrick CM, Green B. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet 2012; 51: 319-30.
30. Young TE, Mangum B. Neofax, 24th edn. Montvale, NJ: Physician Desk Reference Inc, 2011.
31. Young TE. Aminoglycoside therapy in neonates : with particular reference to gentamicin. Neoreviews 2002; 3: e243-48.
32. Rao SC, Srinivasjois R, Hagan R, Ahmed M. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev 2011; (11)CD005091.
33. Kelman AW, Thomson AH, Whiting B, Bryson SM, Steedman DA, Mawer GE, Samba-Donga LA. Estimation of gentamicin clearance and volume of distribution in neonates and young children. Br J Clin Pharmacol 1984; 18: 685-92.
34. Thomson AH, Way S, Bryson SM, McGovern EM, Kelman AW, Whiting B. Population pharmacokinetics of gentamicin in neonates. Dev Pharmacol Ther 1988; 11: 173-9.
35. Izquierdo M, Lanao JM, Cervero L, Jimenez NV, Dominguez-Gil A. Population pharmacokinetics of gentamicin in premature infants. Ther Drug Monit 1992; 14: 177-83.
36. Weber W, Kewitz G, Rost KL, Looby M, Nitz M, Harnisch L. Population kinetics of gentamicin in neonates. Eur J Clin Pharmacol 1993; 44 (Suppl. 1): S23-5.
37. Jensen PD, Edgren BE, Brundage RC. Population pharmacokinetics of gentamicin in neonates using a nonlinear, mixed-effects model. Pharmacotherapy 1992; 12: 178-82.
38. Rocha MJ, Almeida AM, Afonso E, Martins V, Santos J, Leitao F, Falcao AC. The kinetic profile of gentamicin in premature neonates. J Pharm Pharmacol 2000; 52: 1091-7.
39. Stickland MD, Kirkpatrick CM, Begg EJ, Duffull SB, Oddie SJ, Darlow BA. An extended interval dosing method for gentamicin in neonates. J Antimicrob Chemother 2001; 48: 887-93.
40. Stolk LM, Degraeuwe PL, Nieman FH, de Wolf MC, de Boer A. Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin in neonates. Ther Drug Monit 2002; 24: 527-31.
41. Botha JH, du Preez MJ, Adhikari M. Population pharmacokinetics of gentamicin in South African newborns. Eur J Clin Pharmacol 2003; 59: 755-9.
42. DiCenzo R, Forrest A, Slish JC, Cole C, Guillet R. A gentamicin pharmacokinetic population model and once-daily dosing algorithm for neonates. Pharmacotherapy 2003; 23: 585-91.
43. Lanao JM, Calvo MV, Mesa JA, Martin-Suarez A, Carbajosa MT, Miguelez F, Dominguez-Gil A. Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates. J Antimicrob Chemother 2004; 54: 193-8.
44. Lingvall M, Reith D, Broadbent R. The effect of sepsis upon gentamicin pharmacokinetics in neonates. Br J Clin Pharmacol 2005; 59: 54-61.
45. Garcia B, Barcia E, Perez F, Molina IT. Population pharmacokinetics of gentamicin in premature newborns. J Antimicrob Chemother 2006; 58: 372-9.
46. Sherwin CM, Kostan E, Broadbent RS, Medlicott NJ, Reith DM. Evaluation of the effect of intravenous volume expanders upon the volume of distribution of gentamicin in septic neonates. Biopharm Drug Dispos 2009; 30: 276-80.
47. Adelman M, Evans E, Schentag JJ. Two-compartment comparison of gentamicin and tobramycin in normal volunteers. Antimicrob Agents Chemother 1982; 22: 800-4.
48. Schentag JJ, Jusko WJ. Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther 1977; 22: 364-70.
49. Schentag JJ, Jusko WJ, Plaut ME, Cumbo TJ, Vance JW, Abrutyn E. Tissue persistence of gentamicin in man. JAMA 1977; 238: 327-9.
50. Lopez SA, Mulla H, Durward A, Tibby SM. Extended-interval gentamicin: population pharmacokinetics in pediatric critical illness. Pediatr Crit Care Med 2010; 11: 267-74.
51. Laskin OL, Longstreth JA, Smith CR, Lietman PS. Netilmicin and gentamicin multidose kinetics in normal subjects. Clin Pharmacol Ther 1983; 34: 644-50.
52. Nielsen EI, Sandstrom M, Honore PH, Ewald U, Friberg LE. Developmental pharmacokinetics of gentamicin in preterm and term neonates: population modelling of a prospective study. Clin Pharmacokinet 2009; 48: 253-63.
53. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr 2006; 165: 819-29.
54. Besunder JB, Reed MD, Blumer JL. Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part I). Clin Pharmacokinet 1988; 14: 189-216.
55. Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, Chatelut E, Grubb A, Veal GJ, Keir MJ, Holford NH. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol 2009; 24: 67-76.
56. Anderson BJ, Allegaert K, Van den Anker JN, Cossey V, Holford NH. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol 2007; 63: 75-84.
57. Barrington K, Brion LP. Dopamine versus no treatment to prevent renal dysfunction in indomethacin-treated preterm newborn infants. Cochrane Database Syst Rev 2002; (3)CD003213.
58. Seri I, Rudas G, Bors Z, Kanyicska B, Tulassay T. Effects of low-dose dopamine infusion on cardiovascular and renal functions, cerebral blood flow, and plasma catecholamine levels in sick preterm neonates. Pediatr Res 1993; 34: 742-9.
59. Lynch SK, Lemley KV, Polak MJ. The effect of dopamine on glomerular filtration rate in normotensive, oliguric premature neonates. Pediatr Nephrol 2003; 18: 649-52.
60. De Cock RF, Allegaert K, Schreuder MF, Sherwin CM, de Hoog M, van den Anker JN, Danhof M, Knibbe CA. Maturation of the glomerular filtration rate in neonates, as reflected by amikacin clearance. Clin Pharmacokinet 2012; 51: 105-17.
61. Allegaert K, Rayyan M, Anderson BJ. Impact of ibuprofen administration on renal drug clearance in the first weeks of life. Methods Find Exp Clin Pharmacol 2006; 28: 519-22.
62. van den Anker JN, Hop WC, de Groot R, van der Heijden BJ, Broerse HM, Lindemans J, Sauer PJ. Effects of prenatal exposure to betamethasone and indomethacin on the glomerular filtration rate in the preterm infant. Pediatr Res 1994; 36: 578-81.
63. Mercanti I, Boubred F, Simeoni U. Therapeutic closure of the ductus arteriosus: benefits and limitations. J Matern Fetal Neonatal Med 2009; 22 (Suppl. 3): 14-20.
64. Lawson DH, Tilstone WJ, Gray JM, Srivastava PK. Effect of furosemide on the pharmacokinetics of gentamicin in patients. J Clin Pharmacol 1982; 22: 254-8.
65. Bhatt-Mehta V, Donn SM. Gentamicin pharmacokinetics in term newborn infants receiving high-frequency oscillatory ventilation or conventional mechanical ventilation: a case-controlled study. J Perinatol 2003; 23: 559-62.
66. Triginer C, Izquierdo I, Fernandez R, Torrent J, Benito S, Net A, Jane F. Changes in gentamicin pharmacokinetic profiles induced by mechanical ventilation. Eur J Clin Pharmacol 1991; 40: 297-302.
67. Pacifici GM. Clinical pharmacokinetics of aminoglycosides in the neonate: a review. Eur J Clin Pharmacol 2009; 65: 419-27.
68. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am 2003; 17: 503-28.
69. Chattopadhyay B. Newborns and gentamicin-how much and how often? J Antimicrob Chemother 2002; 49: 13-6.
70. Mohamed AF, Nielsen EI, Cars O, Friberg LE. Pharmacokinetic-pharmacodynamic model for gentamicin and its adaptive resistance with predictions of dosing schedules in newborn infants. Antimicrob Agents Chemother 2012; 56: 179-88.
71. Barclay ML, Begg EJ. Aminoglycoside adaptive resistance: importance for effective dosage regimens. Drugs 2001; 61: 713-21.
72. EzeCHiel. [online]. Yverdon-Lausanne: ISyPeM Project. 2013 Jun; Available at http://www.ezechiel.ch/(last accessed 21 March 2014).